A randomized, double-blind, placebo-controlled trial has assessed the efficacy of larazotide acetate in controlling symptoms of coeliac disease. 342 patients with coeliac disease were treated with either placebo, 0.5, 1.0 or 2.0 mg larazotide acetate for 12 weeks in addition to maintaining their gluten-free diet. The 0.5 mg dose was more effective than placebo at reducing symptoms; safety was comparable to that of the placebo group. The higher doses of larazotide acetate were no better than placebo.
References
Lefdfler, D. A. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 10.1053/j.gastro.2015.02.008
Rights and permissions
About this article
Cite this article
Larazotide acetate improves symptoms of coeliac disease more than gluten-free diet alone. Nat Rev Gastroenterol Hepatol 12, 188 (2015). https://doi.org/10.1038/nrgastro.2015.42
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.42
